Skip to main content
. 2020 May 6;7(5):ofaa161. doi: 10.1093/ofid/ofaa161

Table 2.

Outcomes of DFI With Individual MDRO (Within 1 Year)

Entire Cohort PA (n = 94) Non-PA (n = 554) ORa (95% CI) Adjusted HR (95% CI) 3GCR-EC (n = 51) Non- 3GCR-EC (n = 597) ORa (95% CI) Adjusted HR (95% CI) VRE (n = 52) Non-VRE (n = 596) ORa (95% CI) Adjusted HR (95% CI) DFI- MRSA (n = 224) DFI-Non- MRSA (n = 424) ORa (95% CI) Adjusted HR (95% CI)
Recurrent DFI 125 (19.3) 24 (25.5) 101 (18.3) 1.54 (0.92–2.56) 1.55 (0.88–2.74) 14 (27.5) 111 (18.6) 1.66 (0.87–3.17) 2.95 (1.25–6.98) 17 (32.7) 108 (18.1) 2.19 (1.19– 4.06) 2.57 (1.29–5.12) 53 (23.7) 72 (17.0) 1.52 (1.02– 2.26) 1.47 (0.99–2.18)
LEA, No. (%) 88 (13.6) 21 (22.3) 67 (12.1) 2.09 (1.21–3.62) 1.59 (0.88–2.89) 17 (33.3) 71 (11.9) 3.70 (1.97–6.97) 2.28 (0.93–5.62) 12 (23.1) 76 (12.8) 2.05 (1.03– 4.09) 1.50 (0.72–3.09) 28 (12.5) 60 (14.2) 0.87 (0.54– 1.40) 0.84 (0.52–1.35)
Less extensive amputation, No. (%) 315 (48.6) 42 (44.7) 273 (49.3) 0.83 (0.54–1.29) 1.09 (0.66–1.79) 19 (37.3) 296 (49.6) 0.60 (0.33–1.09) 1.11 (0.48–2.53) 25 (40.1) 290 (48.7) 0.98 (0.55– 1.72) 1.10 (0.59–2.05) 105 (46.9) 210 (49.5) 0.89 (0.65– 1.24) 0.92 (0.67–1.28)
Readmissions, No. (%) 391 (60.3) 63 (67.0) 328 (59.2) 1.40 (0.88–2.22) 1.04 (0.62–1.74) 32 (62.8) 359 (60.1) 1.11 (0.62–2.01) 1.34 (0.54–3.31) 38 (73.1) 353 (59.2) 1.87 (0.99– 3.52) 1.42 (0.70–2.86) 138 (61.6) 253 (59.7) 1.08 (0.78– 1.51) 1.10 (0.78–1.53)
Length of stay, median (IQR), d 8 (5 to 12) 10 (6 to 15) 8 (5 to 12) 0.009 4.5 (−3 to 12.7) 11 (7 to 18) 8 (5 to 12) P< .001 6.6 (−5.3 to 20.2) 7.5 (5 to 13.5) 8 (5 to 12) P = .98 −1.7 (−10.6 to 8) 8 (6 to 12) 8 (5 to 12) P = .06 5.5 (0.3 to 11)
Mortality (n = 535), No. (%) 36 (6.7) 7 (8.3) 29 (6.4) 1.32 (0.56–3.12) 0.65 (0.25–1.73) 8 (19.1) 28 (5.7) 3.90 (1.65–9.21) 1.02 (0.22–4.72) 4 (9.1) 32 (6.5) 1.43 (0.48– 4.25) 1.01 (0.32–3.17) 9 (5) 27 (7.7) 0.63 (0.29– 1.36) 0.63 (0.29–1.36)

Abbreviations: 3GCR-EC, third-generation resistant Enterobacteriaceae; CI, confidence interval; DFI, diabetic foot infection; LEA, lower extremity amputation; LOS, length of stay; MDRO, multidrug-resistant organism; MRSA, methicillin-resistant Staphylococcal aureus; OR, odds ratio; PA, Pseudomonas aeruginosa; VRE, vancomycin-resistant Enterococcus.

aFor continuous variables, P values are presented instead of odds ratios (ie, age, Charlson score, ankle-brachial index, hemoglobin A1C, length of stay, duration of treatment).